Association Between CytochromeP4501A2 and CytochromeP4502E1 Gene Polymorphisms and Metabolism of Theophylline

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

102 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-09-30

Study Completion Date

2014-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to determine whether common CYP1A2 and CYP2E1 gene polymorphisms effect metabolism of theophylline in chronic obstructive pulmonary disease patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Association Study Between CYP1A2 Gene Polymorphisms and Metabolism of Theophylline

NCT03015090

Chronic Obstructive Pulmonary Disease

COMPLETED NA

Realize the Current Situation of COPD Patients in China

NCT03131362

Chronic Obstructive Pulmonary Disease COPD

COMPLETED

Genetics of Airway Responsiveness and Lung Function

NCT00005537

Asthma Lung Diseases, Obstructive Chronic Obstructive Pulmonary Disease

COMPLETED

Small Bioactive Molecules in Early COPD Diseases

NCT04950023

Chronic Obstructive Pulmonary Disease

UNKNOWN

Study on the Etiology, Risk Factors and Pathogenesis of COPD Based on Clinical Bioinformatics

NCT05069194

Chronic Obstructive Pulmonary Disease

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Obstructive Pulmonary Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

theophylline

Group Type OTHER

theophylline

Intervention Type DRUG

After oral theophylline 200mg per day for two weeks,bood sample will be collected for determining plasma concentrations of theophylline and it's metabolites and the genotypes of CYP1A2 and CYP2E1

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

theophylline

After oral theophylline 200mg per day for two weeks,bood sample will be collected for determining plasma concentrations of theophylline and it's metabolites and the genotypes of CYP1A2 and CYP2E1

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 18-75 years,COPD patients, male or female;
* regularly visiting our hospital;
* taking a sustained-release preparation of theophylline continuously for at least 2 weeks

Exclusion Criteria

* patients with renal or hepatic dysfunction;
* patients with congestive heart failure;
* patients with hypothyroidism or hyperthyroidism;
* patients currently taking drugs likely to affect theophylline metabolism or who had taken such drugs in the preceding week;
* patients with extreme obesity
* patients with very severe Chronic Obstructive Pulmonary Disease(COPD)

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No